Animal models of multiple sclerosis: The good, the bad and the bottom line

Nature Neuroscience

Volumn 15, Issue 8, 2012, Pages 1074-1077

  Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CUPRIZONE; CXCL13 CHEMOKINE; DIPHTHERIA TOXIN; ETHIDIUM BROMIDE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 23; LYSOPHOSPHATIDYLCHOLINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN; PROTEOLIPID PROTEIN; RANTES; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; C57BL 6 MOUSE; DEMYELINATION; DISEASE COURSE; DISEASE MODEL; GENETIC MODEL; IMMUNE SYSTEM; KNOCKOUT MOUSE; LYMPHOCYTE; MONOCYTE; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PARENCHYMA; PRIORITY JOURNAL; REMYELINIZATION; SUICIDE GENE; TRANSGENIC MOUSE; TRANSLATIONAL RESEARCH;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS;

EID: 84864446952     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3168     Document Type: Article

References (50)

1. Sawcer, S. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214-219 (2011).
2. Ascherio, A. & Munger, K.L. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann. Neurol. 61, 504-513 (2007).
3. Ascherio, A. & Munger, K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288-299 (2007).
4. Pelletier, D. & Hafler, D.A. Fingolimod for multiple sclerosis. N. Engl. J. Med. 366, 339-347 (2012).
5. Prineas, J.W. & Graham, J.S. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann. Neurol. 10, 149-158 (1981).
6. Frohman, E.M., Racke, M.K. & Raine, C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354, 942-955 (2006).
7. Zhang, G.X., Baker, C.M., Kolson, D.L. & Rostami, A.M. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult. Scler. 6, 3-13 (2000).
8. Trapp, B.D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
9. Ferguson, B., Matyszak, M.K., Esiri, M.M. & Petty, V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120, 393-399 (1997).
10. Aboul-Enein, F. & Lassmann, H. Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? Acta Neuropathol. 109, 49-55 (2005).
11. Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000).
12. Lucchinetti, C.F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188-2197 (2011).
13. Kornek, B. et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157, 267-276 (2000).
14. Patrikios, P. et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129, 3165-3172 (2006).
15. Lipton, H.L. Theiler′s virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect. Immun. 11, 1147-1155 (1975).
16. Croxford, A.L., Kurschus, F.C. & Waisman, A. Mouse models for multiple sclerosis: historical facts and future implications. Biochim. Biophys. Acta 1812, 177-183 (2011).
17. Waksman, B.H. & Adams, R.D. A histologic study of the early lesion in experimental allergic encephalomyelitis. Am. J. Pathol. 41, 135-162 (1962).
18. Yasuda, T., Tsumita, T., Nagai, Y., Mitsuzawa, E. & Ohtani, S. Experimental allergic encephalomyelitis (EAE) in mice. I. Induction of EAE with mouse spinal cord homogenate and myelin basic protein. Jpn. J. Exp. Med. 45, 423-427 (1975).
19. Bernard, C.C., Leydon, J. & Mackay, I.R. T cell necessity in the pathogenesis of experimental autoimmune encephalomyelitis in mice. Eur. J. Immunol. 6, 655-660 (1976).
20. Steinman, L. & Zamvil, S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60, 12-21 (2006).
21. Dal Canto, M.C., Melvold, R.W., Kim, B.S. & Miller, S.D. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler′s murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc. Res. Tech. 32, 215-229 (1995).
22. Uccelli, A., Giunti, D., Capello, E., Roccatagliata, L. & Mancardi, G.L. EAE in the common marmoset Callithrix jacchus. Int. MS J. 10, 6-12 (2003).
23. Hart, B.A. et al. Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am. J. Pathol. 153, 649-663 (1998).
24. Paterson, P.Y. & Joseph, E. Smadel Memorial Lecture: neuroimmunologic diseases of animals and humans. Rev. Infect. Dis. 1, 468-482 (1979).
25. Waksman, B.H. Demyelinating disease: evolution of a paradigm. Neurochem. Res. 24, 491-495 (1999).
26. Yednock, T.A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356, 63-66 (1992).
27. Lassmann, H. & Ransohoff, R.M. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol. 25, 132-137 (2004).
28. Fugger, L., Friese, M.A. & Bell, J.I. From genes to function: the next challenge to understanding multiple sclerosis. Nat. Rev. Immunol. 9, 408-417 (2009).
29. De Camargo Furtado, G. et al. Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol. Rev. 182, 122-134 (2001).
30. Ransohoff, R.M. A mighty mouse: building a better model of multiple sclerosis. J. Clin. Invest. 116, 2313-2316 (2006).
31. Ransohoff, R.M., Howe, C.L. & Rodriguez, M. Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends Immunol. 23, 512-516 (2002).
32. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192, 393-404 (2000).
33. + T cells in a model for multiple sclerosis. J. Exp. Med. 194, 669-676 (2001).
34. Berer, K., Wekerle, H. & Krishnamoorthy, G. B cells in spontaneous autoimmune diseases of the central nervous system. Mol. Immunol. 48, 1332-1337 (2011).
35. Hauser, S.L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
36. Miller, S.D. et al. Persistent infection with Theiler′s virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3, 1133-1136 (1997).
37. Rivera-Quiñones, C. et al. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat. Med. 4, 187-193 (1998).
38. Bergmann, C.C., Lane, T.E. & Stohlman, S.A. Coronavirus infection of the central nervous system: host-virus stand-off. Nat. Rev. Microbiol. 4, 121-132 (2006).
39. Matsushima, G.K. & Morell, P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 11, 107-116 (2001).
40. Skripuletz, T., Gudi, V., Hackstette, D. & Stangel, M. De-and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol. Histopathol. 26, 1585-1597 (2011).
41. Liñares, D. et al. Neuronal nitric oxide synthase plays a key role in CNS demyelination. J. Neurosci. 26, 12672-12681 (2006).
42. Liu, L. et al. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 13, 319-326 (2010).
43. Arnett, H.A. et al. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4, 1116-1122 (2001).
44. Ludwin, S.K. Central nervous system demyelination and remyelination in the mouse: an ultrastructural study of cuprizone toxicity. Lab. Invest. 39, 597-612 (1978).
45. Blakemore, W.F. & Franklin, R.J. Remyelination in experimental models of toxin-induced demyelination. Curr. Top. Microbiol. Immunol. 318, 193-212 (2008).
46. Foote, A.K. & Blakemore, W.F. Inflammation stimulates remyelination in areas of chronic demyelination. Brain 128, 528-539 (2005).
47. Blakemore, W.F., Eames, R.A., Smith, K.J. & McDonald, W.I. Remyelination in the spinal cord of the cat following intraspinal injections of lysolecithin. J. Neurol. Sci. 33, 31-43 (1977).
48. Miller, R.H. & Fyffe-Maricich, S.L. Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models. Dis. Model. Mech. 3, 535-539 (2010).
49. Pohl, H.B. et al. Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J. Neurosci. 31, 1069-1080 (2011).
50. Traka, M. et al. A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain 133, 3017-3029 (2010).